Anti-Diabetes Drugs - South America

  • South America
  • The Anti-Diabetes Drugs market in South America is expected to witness significant growth in the coming years.
  • According to projections, the revenue in this market is anticipated to reach US$2.31bn by 2024.
  • Furthermore, it is predicted that the market will experience a steady annual growth rate of 5.39% from 2024 to 2028.
  • As a result, the market volume is estimated to reach US$2.85bn by 2028.
  • When comparing the global scenario, it is worth noting that United States is expected to generate the highest revenue in this market, with a projected amount of US$35,630.00m in 2024.
  • The demand for anti-diabetes drugs in South America is surging due to an increasing prevalence of diabetes in the region.

Key regions: India, Canada, Australia, France, Italy

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Anti-Diabetes Drugs market in South America has been steadily growing over the past few years.

Customer preferences:
Customers in South America are increasingly looking for more effective and convenient anti-diabetes drugs that can help them manage their condition. They are also looking for drugs that are affordable and easily accessible.

Trends in the market:
Brazil is the largest market for anti-diabetes drugs in South America, accounting for a significant portion of the region's market share. The country's aging population and rising obesity rates have contributed to the growth of the anti-diabetes drugs market. Additionally, the increasing prevalence of type 2 diabetes in the country has also led to an increase in demand for anti-diabetes drugs. Argentina and Colombia are also emerging markets for anti-diabetes drugs in South America. The increasing prevalence of diabetes in these countries has led to a rise in demand for anti-diabetes drugs.

Local special circumstances:
One of the unique challenges in the South American market is the lack of access to healthcare in certain areas. This can make it difficult for patients to access necessary medications, including anti-diabetes drugs. Additionally, the high cost of medication can also be a barrier to treatment for many patients.

Underlying macroeconomic factors:
The South American economy has been experiencing slow growth over the past few years, which has affected the healthcare industry. However, the demand for anti-diabetes drugs has remained strong despite the economic challenges. The increasing prevalence of diabetes in the region has been a key driver of growth in the market. Additionally, the growing middle class in South America has also contributed to the growth of the anti-diabetes drugs market as more people are able to afford treatment.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)